Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Elevated Levels of IgG2 Antibodies Protect Some Types of Gram-Negative Bacteria

By BiotechDaily International staff writers
Posted on 27 Aug 2014
Image: Lipopolysaccharides (LPS) are large molecules consisting of a lipid and a polysaccharide composed of O-antigen, outer core and inner core joined by a covalent bond. They are found in the outer membrane of Gram-negative bacteria, and elicit strong immune responses in animals (Photo courtesy of Wikimedia Commons).
Image: Lipopolysaccharides (LPS) are large molecules consisting of a lipid and a polysaccharide composed of O-antigen, outer core and inner core joined by a covalent bond. They are found in the outer membrane of Gram-negative bacteria, and elicit strong immune responses in animals (Photo courtesy of Wikimedia Commons).
The finding that an overabundance of a certain class of antibodies protects some bacteria from the effects of antibiotics has marked implications for our understanding of the protection generated by natural infections and for the design of vaccines, which should avoid inducing such inhibitory antibodies.

Investigators at the University of Birmingham (United Kingdom) worked with patients that had bronchiectasis—a chronic infection characterized by persistent cough, shortness of breath, and chest pain—or lung infection caused by the bacterium Pseudomonas aeruginosa.

They reported in the August 2014 online edition of the Journal of Experimental Medicine that in a significant portion of these patients, antibodies protected the bacterium from complement-mediated killing. Strains that resisted antibody-induced, complement-mediated killing produced a lipopolysaccharide containing O-antigen. In particular, they found that inhibition of antibody-mediated killing was caused by excess production of O-antigen–specific antibodies of the IgG2 class. Depletion of IgG2 to O-antigen restored the ability of sera to kill strains with long-chain O-antigen.

Patients with impaired serum-mediated killing of P. aeruginosa by IgG2 were shown to have poorer respiratory function than infected patients who did not produce the inhibitory antibody.

The authors suggested that excessive binding of IgG2 to O-antigen shielded the bacterium from other antibodies that could induce complement-mediated killing. Since there is significant sharing of O-antigen structure between different Gram-negative bacteria, this IgG2-mediated impairment of killing could be operating in other Gram-negative infections as well. These findings have marked implications for understanding the nature of protection generated by natural infections and for the design of vaccines, which should avoid inducing IgG2 class inhibitory antibodies.

Related Links:

University of Birmingham 



Channels

Drug Discovery

view channel
Image: Cancer cells were treated with a control (left) and the overstimulating compound MCB-613 (right) (Photo courtesy of Dr. Lei Wang, Baylor University College of Medicine).

Drug Candidate Propels Cancer Cells into Fatal Overdrive

A candidate drug that destroys cancer cells by stimulating them to produce more proteins than the cells can actually process was shown to kill a wide variety of cancer cells in culture and to inhibit tumor... Read more

Lab Technologies

view channel
Image: The Synergy Neo2 Multi-Mode Reader recently received Cisbio HTRF certification (Photo courtesy of BioTek Instruments Inc.).

High-Speed Multimode Microplate Reader Receives Homogenous Time-Resolved Fluorescence Certification

A new high-performance, high-speed microplate reader has received HTRF (homogenous time-resolved fluorescence) accreditation that certifies that it complies with standards for detection set by a major... Read more

Business

view channel

Innovative Microbial Diagnostics Developer Acquired by Biomedical Giant

A biotech company noted for its development of innovative products in the field of molecular microbiology diagnostics has been acquired by one of the world's largest biomedical corporations. GeneWEAVE BioSciences, Inc.(Los Gatos, CA, USA) and Roche (Basel, Switzerland) have announced that Roche will be purchasing the... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.